Compare BioNano Genomics Inc (BNGO) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Wipro Limited — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Wipro Limited trades at $1.86 (market cap $18.57B). The key difference: Wipro Limited is far larger — about 1406.8× BioNano Genomics Inc's market cap, and Wipro Limited pays a 10.42% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | WIT | |
|---|---|---|
Market Cap | $13.20M | $18.57B |
Sector | Health | Technology |
52-Week High | $4.92 | $3.06 |
52-Week Low | $1.09 | $1.82 |
Enterprise Value | $15.81M | $14.96B |
Dividend Yield | — | 10.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
WIT trades at $1.90, up 1.6% with bearish technical signals despite recent AI partnership announcements. The company shows mixed fundamentals with declining revenue from $904.9B in 2023 to $890.9B in 2025, though net income improved to $131.4B with a 14.74% margin. Recent earnings misses and weak guidance have tempered investor enthusiasm despite strong cash flow generation and AI initiatives.
WIT presents a cautious outlook with analyst consensus leaning bearish (19% buy vs 33% sell). While valuation appears reasonable (P/E 14.27) and AI partnerships offer growth potential, persistent revenue declines and execution risks in a competitive IT services market warrant careful monitoring. The stock faces near-term pressure from technical weakness and growth concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
